- <![CDATA[Comparing Approved Checkpoint Inhibitor Regimens and Optimal Treatment Duration]]><![CDATA[New SGO 2026 data shows frontline checkpoint inhibitors deliver 4-year survival gains and near-zero relapse after two years in DMMR cancers.]]>onclive · 2mo ago↗ source
- <![CDATA[Disease Assessment and Mutational Testing in Progressive CLL]]><![CDATA[Experts discuss relapsed CLL workup, using PET-CT and lymph node biopsy to rule out Richter’s, plus resistance testing to guide next therapy.]]>onclive · 2mo ago↗ source
- <![CDATA[Clinical Scenario Presentation and Treatment Approach for Progressive Disease]]><![CDATA[Experts weigh mutation testing, comorbidities, and patient preference to guide second-line CLL options after BTK inhibitor resistance.]]>